News Myriad Genetics, Inc.

Equities

MYGN

US62855J1043

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-17 pm EDT			5-day change	1st Jan Change
18.64 ^USD	-1.48%		-8.00%	-2.61%

Mar. 20	Myriad Genetics Gets US Patent for SneakPeek Snap Device	MT
Feb. 27	Transcript : Myriad Genetics, Inc., Q4 2023 Earnings Call, Feb 27, 2024

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel Prenatal Screen	Apr. 17	AQ
Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor	Apr. 17	GL
New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen	Apr. 16	GL
Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing	Apr. 09	GL
Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing	Apr. 09	AQ
Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date	Mar. 21	GL
Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date	Mar. 21	AQ
Myriad Genetics Gets US Patent for SneakPeek Snap Device	Mar. 20	MT
Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device	Mar. 20	GL
Myriad: Q4 Earnings Snapshot	Feb. 27	AQ
Transcript : Myriad Genetics, Inc., Q4 2023 Earnings Call, Feb 27, 2024	Feb. 27
Earnings Flash (MYGN) MYRIAD GENETICS Reports Q4 EPS $0.04, vs. Street Est of $0.01	Feb. 27	MT
(MYGN) MYRIAD GENETICS Forecasts 2024 Revenue Range $820M - $840M	Feb. 27	MT
Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the Fourth Quarter 2023; Raising 2024 Revenue Guidance	Feb. 27	GL
Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the Fourth Quarter 2023; Raising 2024 Revenue Guidance	Feb. 27	AQ
Myriad Genetics, Inc. Provides Revenue Guidance for the First Quarter 2024	Feb. 27	CI
Myriad Genetics, Inc. Updates Revenue Guidance for the Fiscal Year 2024	Feb. 27	CI
Myriad Genetics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
Myriad Genetics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 27	CI
Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3	Feb. 27	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Myriad Genetics, Inc.

Equities

MYGN

US62855J1043

Summary

Filters